February 27, 2009
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.W.
Washington, D.C. 20549
100 F Street, N.W.
Washington, D.C. 20549
Re: Novogen Limited
Ladies and Gentlemen:
Novogen Limited (the “Company”) is in receipt of the comment letter, dated February 24, 2009, from the staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “SEC”) with respect to the Company’s Annual Report on Form 20-F for the fiscal year ended June 30, 2008 (File No. 000-29962).
The Company will submit its written response to the comments raised by the Staff in the letter to the SEC via EDGAR no later than Tuesday, March 24, 2009.
| NOVOGEN LIMITED | ||||||
| By: | /s/ David Seaton | |||||
| Name: | David Seaton | |||||
| Title: | Chief Financial Officer | |||||
Novogen Limitedabn37 063 259 754 140 Wicks Road, North Ryde NSW 2113, Australia Telephone +61 2 9878 0088 Facsimile +61 2 9878 0055 novogen@novogen.com www.novogen.com